Identification/NN
of/IN
neoantigens/NNS
derived/VBN
from/IN
alternative/JJ
splicing/NN
and/CC
RNA/NN
modification/NN
./.
====================
The/DT
acquisition/NN
of/IN
somatic/JJ
mutations/NNS
is/VBZ
the/DT
most/JJS
common/JJ
event/NN
in/IN
cancer/NN
./.
====================
Neoantigens/NNS
expressed/VBN
from/IN
genes/NNS
with/IN
mutations/NNS
acquired/VBN
during/IN
carcinogenesis/NN
can/MD
be/VB
tumor-specific/JJ
./.
====================
Since/IN
the/DT
immune/JJ
system/NN
recognizes/VBZ
tumor-specific/JJ
peptides/NNS
,/,
they/PRP
are/VBP
potential/JJ
targets/NNS
for/IN
personalized/VBN
neoantigen-based/VBN
immunotherapy/NN
./.
====================
However/RB
,/,
the/DT
discovery/NN
of/IN
druggable/JJ
neoantigens/NNS
remains/VBZ
challenging/JJ
,/,
suggesting/VBG
that/IN
a/DT
deeper/JJ
understanding/VBG
of/IN
the/DT
mechanism/NN
of/IN
neoantigen/NN
generation/NN
and/CC
better/RBR
strategies/NNS
to/TO
identify/VB
them/PRP
will/MD
be/VB
required/VBN
to/TO
realize/VB
the/DT
promise/JJ
of/IN
neoantigen-based/JJ
immunotherapy/NN
./.
====================
Alternative/JJ
splicing/NN
and/CC
RNA/NN
editing/VBG
events/NNS
are/VBP
emerging/VBG
mechanisms/NNS
leading/VBG
to/TO
neoantigen/NN
production/NN
./.
====================
In/IN
this/DT
review/NN
,/,
we/PRP
outline/VBP
recent/JJ
work/NN
involving/VBG
the/DT
large-scale/JJ
screening/NN
of/IN
neoantigens/NNS
produced/VBN
by/IN
alternative/JJ
splicing/NN
and/CC
RNA/NN
editing/VBG
./.
====================
We/PRP
also/RB
describe/VBP
strategies/NNS
to/TO
predict/VB
and/CC
validate/NN
neoantigens/NNS
from/IN
RNA/NN
sequencing/NN
data/NNS
./.
====================
Since/IN
the/DT
immune/JJ
system/NN
recognizes/VBZ
tumor-specific/JJ
peptides/NNS
,/,
they/PRP
are/VBP
potential/JJ
targets/NNS
for/IN
personalized/VBN
neoantigen-based/VBN
immunotherapy/NN
./.
====================
They/PRP
are/VBP
presented/VBN
by/IN
the/DT
major/JJ
histocompatibility/NN
complex/NN
(/(
MHC/NN
)/)
on/IN
the/DT
surface/NN
of/IN
tumor/NN
cells/NNS
,/,
which/WDT
can/MD
be/VB
recognized/VBN
and/CC
killed/VBD
by/IN
T/NN
cells/NNS
./.
====================
These/DT
antigenic/JJ
peptides/NNS
are/VBP
largely/RB
classified/VBN
into/IN
three/CD
groups/NNS
:/:
viral/JJ
antigens/NNS
,/,
cancer/NN
germline/NN
antigens/NNS
,/,
and/CC
mutation-derived/JJ
neoantigens/NNS
[/(
1/CD
]/)
./.
====================
Among/IN
them/PRP
,/,
mutation-derived/VBN
neoantigens/NNS
have/VBP
been/VBN
focused/VBN
in/IN
cancer/NN
genomics/NNS
because/IN
the/DT
causal/JJ
role/NN
of/IN
somatic/JJ
mutations/NNS
in/IN
cancer/NN
have/VBP
been/VBN
well-studied/VBN
./.
====================
Indeed/RB
,/,
the/DT
mutation/NN
burden/NN
of/IN
a/DT
tumor/NN
is/VBZ
known/VBN
to/TO
be/VB
correlated/VBN
with/IN
its/PRP$
response/NN
to/TO
immunotherapy/NN
[/(
2/CD
]/)
./.
====================
However/RB
,/,
exome/JJ
analysis–based/VBD
immunotherapy/NN
strategies/NNS
have/VBP
limitations/NNS
,/,
since/IN
they/PRP
can/MD
identify/VB
only/RB
neoantigen/NN
candidates/NNS
occurring/VBG
at/IN
the/DT
DNA/NN
level/NN
[/(
3/CD
]/)
./.
====================
This/DT
suggest/VBP
that/IN
a/DT
deeper/JJ
understanding/NN
of/IN
the/DT
generation/NN
of/IN
neoantigens/NNS
and/CC
better/RBR
strategies/NNS
to/TO
identify/VB
them/PRP
will/MD
be/VB
required/VBN
to/TO
improve/VB
neoantigen-based/VBN
immunotherapy/NN
./.
====================
Recent/JJ
progress/NN
in/IN
sequencing/NN
technologies/NNS
has/VBZ
enabled/VBN
the/DT
profiling/VBG
of/IN
RNA/NN
processing/NN
events/NNS
caused/VBD
by/IN
various/JJ
forms/NNS
of/IN
post-transcriptional/JJ
regulation/NN
./.
====================
In/IN
particular/JJ
,/,
alternative/JJ
splicing/NN
and/CC
RNA/NN
editing/VBG
have/VBP
drawn/VBN
considerable/JJ
attention/NN
since/IN
they/PRP
promote/VBP
proteome/JJ
diversity/NN
through/IN
changes/NNS
in/IN
amino/NN
acid/NN
sequences/NNS
./.
====================
In/IN
addition/NN
,/,
the/DT
transcript/NN
isoforms/NNS
are/VBP
easily/RB
detectable/JJ
utilizing/VBG
conventional/JJ
RNA/NN
sequencing/NN
(/(
RNA-Seq/NN
)/)
data/NNS
if/IN
proper/JJ
computer-based/VBD
methods/NNS
are/VBP
applied/VBN
./.
====================
Accordingly/RB
,/,
analyses/NNS
of/IN
large-scale/JJ
RNA-Seq/NN
data/NNS
have/VBP
shown/VBN
the/DT
genome-wide/NN
prevalence/NN
and/CC
regulation/NN
of/IN
alternative/JJ
splicing/NN
and/CC
RNA/NN
editing/VBG
[/(
4,5/CD
]/)
./.
====================
Data/NNS
sources/NNS
such/JJ
as/IN
The/DT
Cancer/NN
Genome/NN
Atlas/NNS
(/(
TCGA/NN
)/)
and/CC
the/DT
Genotype-Tissue/NN
Expression/NN
(/(
GTEx/NN
)/)
project/VBP
have/VBP
enabled/VBN
systematic/JJ
investigations/NNS
of/IN
their/PRP$
association/NN
with/IN
cancer/NN
./.
====================
Investigators/NNS
have/VBP
shown/VBN
that/IN
these/DT
RNA/NN
processing/NN
events/NNS
are/VBP
significantly/RB
more/RBR
frequent/JJ
in/IN
cancer/NN
samples/NNS
than/IN
in/IN
matched/VBN
normal/JJ
samples/NNS
,/,
contributing/VBG
to/TO
antigenic/JJ
diversity/NN
[/(
6,7/CD
]/)
./.
====================
Of/IN
note/NN
,/,
like/IN
somatic/JJ
mutations/NNS
,/,
alternative/JJ
splicing/NN
and/CC
RNA/NN
editing/VBG
can/MD
produce/VB
cancer-specific/JJ
antigens/NNS
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
Genetic/JJ
alterations/NNS
(/(
marked/JJ
by/IN
an/DT
orange/NN
or/CC
pink/VBP
color/JJ
in/IN
the/DT
figure/NN
)/)
can/MD
occur/VB
after/IN
transcription/NN
./.
====================
As/IN
a/DT
result/NN
,/,
unlike/IN
somatic/JJ
mutations/NNS
,/,
RNA-level/JJ
genomic/JJ
changes/NNS
are/VBP
not/RB
preserved/VBN
in/IN
offspring/VBG
cells/NNS
./.
====================
Another/DT
noteworthy/NN
difference/NN
is/VBZ
that/DT
the/DT
altered/JJ
transcripts/NNS
have/VBP
a/DT
wide/JJ
range/NN
of/IN
expression/NN
levels/NNS
depending/VBG
on/IN
environmental/JJ
conditions/NNS
./.
====================
Therefore/RB
,/,
alternative/JJ
splicing/NN
and/CC
RNA/NN
editing/VBG
can/MD
be/VB
quantified/VBN
using/VBG
numerical/JJ
values/NNS
ranging/VBG
from/IN
0/CD
%/NN
to/TO
100/CD
%/NN
,/,
indicating/VBG
the/DT
need/NN
for/IN
user-defined/VBN
thresholds/NNS
for/IN
modification/NN
calling/JJ
./.
====================
Recent/JJ
studies/NNS
have/VBP
reported/VBN
that/IN
cancer-specific/JJ
RNA/NN
processing/NN
can/MD
be/VB
a/DT
source/NN
of/IN
immunogenic/JJ
epitopes/NNS
[/(
8,9/CD
]/)
./.
====================
In/IN
this/DT
review/NN
,/,
we/PRP
outline/VBP
recent/JJ
work/NN
involving/VBG
the/DT
large-scale/JJ
screening/NN
of/IN
neoantigens/NNS
produced/VBN
by/IN
alternative/JJ
splicing/NN
and/CC
RNA/NN
editing/VBG
./.
====================
We/PRP
also/RB
describe/VBP
analytical/JJ
strategies/NNS
to/TO
predict/VB
and/CC
validate/NN
neoantigens/NNS
from/IN
RNA-Seq/NN
data/NNS
./.
====================
Alternative/JJ
splicing/NN
can/MD
produce/VB
multiple/JJ
transcripts/NNS
according/VBG
to/TO
the/DT
patterns/NNS
through/IN
which/WDT
exons/NNS
and/CC
introns/NNS
are/VBP
joined/VBN
(/(
Fig/NN
./.
====================
2A/NN
)/)
./.
====================
Alternative/JJ
splicing/NN
is/VBZ
known/VBN
to/TO
affect/VB
more/RBR
than/IN
90/CD
%/NN
of/IN
multi-exon/JJ
human/JJ
genes/NNS
[/(
10/CD
]/)
./.
====================
The/DT
basic/JJ
patterns/NNS
include/VBP
exon/NN
skipping/NN
,/,
the/DT
use/NN
of/IN
alternative/JJ
5/CD
'/``
or/CC
3/CD
'/``
splice/NN
sites/NNS
,/,
mutually/RB
exclusive/JJ
exons/NNS
,/,
and/CC
intron/NN
retention/NN
./.
====================
Exon/NN
skipping/NN
is/VBZ
the/DT
most/JJS
common/JJ
type/NN
of/IN
alternative/JJ
splicing/NN
in/IN
animals/NNS
,/,
whereas/IN
intron/NN
retention/NN
is/VBZ
the/DT
least/JJS
prevalent/JJ
form/VBP
[/(
11/CD
]/)
./.
====================
The/DT
functional/JJ
consequences/NNS
of/IN
alternative/JJ
splicing/NN
can/MD
be/VB
predicted/VBN
using/VBG
various/JJ
annotation/NN
data/NNS
,/,
with/IN
possibilities/NNS
including/VBG
the/DT
gain/loss/NN
of/IN
protein/NN
domains/NNS
,/,
signal/NN
peptides/NNS
,/,
and/CC
coding/VBG
potential/JJ
[/(
12,13/CD
]/)
./.
====================
Intron/NN
retention/NN
often/RB
leads/VBZ
to/TO
nonsense-mediated/JJ
decay/NN
(/(
NMD/NN
)/)
by/IN
introducing/VBG
a/DT
premature/JJ
termination/NN
codon/NN
,/,
resulting/VBG
in/IN
reduced/VBN
gene/NN
expression/NN
[/(
14/CD
]/)
./.
====================
These/DT
RNA-level/JJ
changes/NNS
can/MD
be/VB
further/RBR
propagated/VBN
to/TO
proteomic/JJ
changes/NNS
through/IN
their/PRP$
effects/NNS
on/IN
protein-protein/JJ
interaction/NN
[/(
15/CD
]/)
./.
====================
Numerous/JJ
computational/JJ
methods/NNS
have/VBP
been/VBN
developed/VBN
to/TO
identify/VB
regulated/VBN
splicing/NN
events/NNS
in/IN
RNA-Seq/NN
data/NNS
and/CC
to/TO
predict/VB
their/PRP$
upstream/JJ
regulators/NNS
in/IN
a/DT
genome-wide/JJ
manner/NN
[/(
16/CD
]/)
./.
====================
Bioinformatics/NNS
tools/NNS
are/VBP
largely/RB
classified/VBN
into/IN
two/CD
groups/NNS
:/:
tools/NNS
to/TO
examine/VB
known/VBN
events/NNS
and/CC
tools/NNS
capable/JJ
of/IN
detecting/VBG
novel/JJ
events/NNS
./.
====================
The/DT
latter/JJ
tools/NNS
are/VBP
useful/JJ
for/IN
uncovering/VBG
unannotated/JJ
cancer-specific/JJ
events/NNS
,/,
but/CC
their/PRP$
algorithms/NNS
are/VBP
complicated/VBN
,/,
and/CC
the/DT
running/JJ
time/NN
is/VBZ
generally/RB
longer/RBR
./.
====================
Numerous/JJ
studies/NNS
have/VBP
revealed/VBN
cancer-specific/JJ
splicing/NN
changes/NNS
,/,
suggesting/VBG
their/PRP$
applicability/NN
for/IN
cancer/NN
diagnosis/NN
and/CC
therapy/NN
[/(
17-19/CD
]/)
./.
====================
Recent/JJ
pan-cancer/NN
analyses/NNS
using/VBG
TCGA/NN
data/NNS
identified/VBD
that/WDT
alternative/JJ
splicing/NN
events/NNS
are/VBP
indeed/RB
frequently/RB
altered/JJ
in/IN
cancer/NN
and/CC
some/DT
of/IN
them/PRP
can/MD
contribute/VB
to/TO
the/DT
oncogenic/JJ
process/NN
./.
====================
The/DT
altered/JJ
events/NNS
take/VBP
place/NN
through/IN
a/DT
variety/NN
of/IN
cis-/JJ
and/CC
trans-acting/JJ
regulatory/JJ
factors/NNS
./.
====================
Aberrant/JJ
splicing/NN
patterns/NNS
can/MD
be/VB
induced/VBN
by/IN
genetic/JJ
variants/NNS
in/IN
splicing/NN
regulatory/JJ
sequences/NNS
around/IN
splice/NN
sites/NNS
./.
====================
The/DT
variants/NNS
near/JJ
splice/NN
sites/NNS
are/VBP
more/RBR
likely/JJ
to/TO
have/VB
functional/JJ
effects/NNS
on/IN
splicing/NN
by/IN
disrupting/VBG
existing/VBG
splice/NN
sites/NNS
or/CC
creating/VBG
new/JJ
sites/NNS
[/(
20,21/CD
]/)
./.
====================
In/IN
addition/NN
to/TO
variants/NNS
that/WDT
directly/RB
change/NN
splice/NN
sites/NNS
,/,
common/JJ
variants/NNS
throughout/IN
the/DT
genome/NN
can/MD
be/VB
associated/VBN
with/IN
the/DT
splicing/NN
phenotype/NN
./.
====================
These/DT
are/VBP
termed/VBN
splicing/NN
quantitative/JJ
trait/NN
loci/NNS
(/(
sQTL/NN
)/)
,/,
and/CC
they/PRP
can/MD
be/VB
analyzed/VBN
by/IN
integrating/VBG
population-scale/JJ
genotype/NN
and/CC
RNA-Seq/NN
data/NNS
[/(
22,23/CD
]/)
./.
====================
Lastly/RB
,/,
trans-acting/JJ
splicing/NN
regulators/NNS
can/MD
activate/VB
or/CC
repress/VBP
splicing/NN
of/IN
their/PRP$
target/NN
exons/NNS
[/(
24/CD
]/)
./.
====================
With/IN
growing/VBG
interest/NN
in/IN
cancer/NN
immunotherapy/NN
,/,
two/CD
recent/JJ
studies/NNS
evaluated/VBD
the/DT
contributions/NNS
of/IN
alternative/JJ
splicing/NN
to/TO
neoantigen/NN
production/NN
./.
====================
The/DT
first/JJ
study/NN
performed/VBD
a/DT
comprehensive/JJ
analysis/NN
of/IN
alternative/JJ
splicing/NN
with/IN
the/DT
development/NN
of/IN
an/DT
integrated/JJ
workflow/NN
utilizing/VBG
large-scale/JJ
genomics/NNS
datasets/NNS
[/(
7/CD
]/)
./.
====================
Kahles/NNS
et/FW
al/JJ
./.
====================
[/(
25/CD
]/)
identified/VBD
quantitative/JJ
differences/NNS
in/IN
splicing/NN
between/IN
cancer/NN
and/CC
normal/JJ
samples/NNS
,/,
and/CC
their/PRP$
enrichment/JJ
in/IN
splicing/NN
categories/NNS
also/RB
differed/VBD
./.
====================
For/IN
example/NN
,/,
splicing/NN
regulation/NN
in/IN
cancer/NN
samples/NNS
was/VBD
enhanced/VBN
in/IN
the/DT
categories/NNS
of/IN
alternative/JJ
3/CD
'/``
splice/NN
sites/NNS
and/CC
mutually/RB
exclusive/JJ
exons/NNS
./.
====================
That/DT
research/NN
group/NN
previously/RB
developed/VBD
the/DT
SplAdder/NN
toolkit/NN
to/TO
identify/VB
novel/JJ
splicing/NN
events/NNS
with/IN
good/JJ
performance/NN
in/IN
a/DT
large/JJ
population/NN
[/(
25/CD
]/)
./.
====================
Using/VBG
this/DT
tool/NN
,/,
they/PRP
identified/VBD
251,000/CD
novel/JJ
exon-exon/JJ
junctions/NNS
(/(
referred/VBN
to/TO
as/IN
neojunctions/NNS
)/)
with/IN
an/DT
average/NN
of/IN
930/CD
per/FW
cancer/NN
sample/NN
./.
====================
The/DT
cancer-specific/JJ
junctions/NNS
should/MD
be/VB
absent/JJ
in/IN
the/DT
GTEx/JJ
reference/VBP
data/NNS
,/,
since/IN
they/PRP
are/VBP
rarely/RB
expressed/VBN
in/IN
normal/JJ
reference/NN
samples/NNS
[/(
7/CD
]/)
./.
====================
A/DT
proteomics/NNS
database/NN
,/,
containing/VBG
Clinical/JJ
Proteomic/JJ
Tumor/NN
Analysis/NN
Consortium/NN
(/(
CPTAC/NN
)/)
mass/NN
spectrometry/NN
data/NNS
,/,
was/VBD
used/VBN
to/TO
confirm/VB
the/DT
expression/NN
of/IN
peptides/NNS
derived/VBN
from/IN
alternative/JJ
splicing/NN
./.
====================
An/DT
important/JJ
finding/NN
was/VBD
that/DT
neoantigens/NNS
derived/VBN
from/IN
alternative/JJ
splicing/NN
events/NNS
were/VBD
more/RBR
frequent/JJ
than/IN
single-nucleotide/JJ
variants/NNS
,/,
even/RB
though/IN
the/DT
former/JJ
category/NN
had/VBD
relatively/RB
low/JJ
levels/NNS
of/IN
expression/NN
./.
====================
Lastly/RB
,/,
the/DT
study/NN
pointed/VBD
out/RP
that/DT
their/PRP$
predictions/NNS
of/IN
neoantigens/NNS
were/VBD
not/RB
complete/JJ
for/IN
several/JJ
reasons/NNS
,/,
including/VBG
the/DT
fact/NN
that/IN
they/PRP
excluded/VBD
intron/NN
retention/NN
events/NNS
from/IN
neoantigen/NN
prediction/NN
./.
====================
In/IN
this/DT
context/NN
,/,
a/DT
recent/JJ
study/NN
was/VBD
meaningful/JJ
because/IN
it/PRP
focused/VBD
on/IN
intron/NN
retention/NN
,/,
a/DT
splicing/NN
type/NN
that/DT
was/VBD
neglected/VBN
in/IN
the/DT
previous/JJ
study/NN
./.
====================
Intron-containing/VBG
peptides/NNS
are/VBP
often/RB
subject/JJ
to/TO
degradation/NN
by/IN
NMD/NN
,/,
and/CC
the/DT
cleaved/VBN
peptides/NNS
can/MD
be/VB
presented/VBN
on/IN
MHC/NN
class/NN
I/CD
molecules/NNS
./.
====================
Smart/NN
et/FW
al/JJ
./.
====================
[/(
26/CD
]/)
developed/VBD
a/DT
computational/JJ
strategy/NN
to/TO
detect/VB
intron/NN
retention/NN
events/NNS
from/IN
RNA-Seq/NN
data/NNS
./.
====================
Using/VBG
two/CD
cohorts/NNS
of/IN
melanoma/NN
patient/NN
data/NNS
with/IN
checkpoint/NN
inhibitor/NN
treatment/NN
,/,
they/PRP
found/VBD
that/IN
intron/NN
retention/NN
was/VBD
an/DT
important/JJ
mechanism/NN
for/IN
neoantigen/NN
prediction/NN
that/DT
should/MD
be/VB
checked/VBN
,/,
because/IN
as/IN
many/JJ
intron-retaining/JJ
neoantigens/NNS
as/IN
somatic/JJ
mutation–derived/JJ
neoantigens/NNS
were/VBD
present/JJ
in/IN
most/JJS
patient/NN
samples/NNS
./.
====================
However/RB
,/,
they/PRP
were/VBD
not/RB
associated/VBN
with/IN
the/DT
clinical/JJ
outcomes/NNS
of/IN
checkpoint/NN
inhibitor/NN
therapy/NN
,/,
unlike/IN
somatic/JJ
mutation–derived/JJ
neoantigens/NNS
./.
====================
Taken/VBN
together/RB
,/,
the/DT
above/JJ
two/CD
studies/NNS
significantly/RB
expanded/VBN
the/DT
boundaries/NNS
of/IN
neoantigen/NN
prediction/NN
by/IN
considering/VBG
both/CC
DNA/NN
and/CC
RNA/NN
alterations/NNS
./.
====================
RNA/NN
modifications/NNS
change/NN
the/DT
biochemical/JJ
composition/NN
of/IN
RNA/NN
molecules/NNS
and/CC
affect/VB
their/PRP$
structure/NN
and/CC
metabolism/NN
./.
====================
RNA/NN
modifications/NNS
are/VBP
called/VBN
the/DT
“/NN
epitranscriptome/JJ
,/,
”/NNP
meaning/VBG
that/DT
they/PRP
are/VBP
forms/NNS
of/IN
post-transcriptional/JJ
alterations/NNS
that/IN
do/VBP
not/RB
affect/VB
the/DT
RNA/NN
sequence/NN
,/,
in/IN
analogy/NN
to/TO
how/WRB
the/DT
term/NN
“/NN
epigenome/JJ
”/CD
describes/VBZ
functionally/RB
relevant/JJ
changes/NNS
that/IN
do/VBP
not/RB
involve/VB
changes/NNS
in/IN
the/DT
DNA/NN
sequence/NN
[/(
27/CD
]/)
./.
====================
Recent/JJ
studies/NNS
have/VBP
revealed/VBN
that/IN
many/JJ
of/IN
these/DT
modifications/NNS
are/VBP
remarkably/RB
widespread/JJ
across/IN
the/DT
genome/NN
,/,
evolutionarily/RB
conserved/VBN
,/,
and/CC
functionally/RB
important/JJ
./.
====================
More/RBR
than/IN
100/CD
distinct/JJ
types/NNS
of/IN
RNA/NN
modifications/NNS
have/VBP
been/VBN
identified/VBN
./.
====================
Most/JJS
RNA/NN
modifications/NNS
do/VBP
not/RB
change/VB
nucleotides/NNS
,/,
but/CC
RNA/NN
editing/VBG
is/VBZ
accompanied/VBN
by/IN
a/DT
change/NN
in/IN
the/DT
RNA/NN
sequence/NN
itself/PRP
./.
====================
One/CD
of/IN
the/DT
common/JJ
examples/NNS
is/VBZ
the/DT
deamination/NN
of/IN
adenosine/NN
(/(
A/DT
)/)
to/TO
inosine/VB
(/(
I/NN
)/)
,/,
which/WDT
is/VBZ
recognized/VBN
as/IN
guanosine/NN
(/(
G/NN
)/)
in/IN
RNA/NN
sequencing/NN
./.
====================
The/DT
A-to-I/JJ
editing/VBG
is/VBZ
mediated/VBN
by/IN
the/DT
adenosine/NN
deaminases/NNS
acting/VBG
on/IN
RNA/NN
(/(
ADARs/NNS
)/)
protein/NN
family/NN
,/,
which/WDT
prefers/VBZ
double-stranded/JJ
RNA/NN
structure/NN
[/(
28/CD
]/)
(/(
Fig/NN
./.
====================
2B/NN
)/)
./.
====================
The/DT
edited/JJ
sites/NNS
are/VBP
mostly/RB
found/VBN
in/IN
noncoding/JJ
regions/NNS
of/IN
RNA/NN
,/,
which/WDT
may/MD
have/VB
regulatory/JJ
potential/JJ
./.
====================
RNA/NN
editing/VBG
of/IN
the/DT
protein-coding/VBG
sequence/NN
can/MD
result/VB
in/IN
the/DT
expression/NN
of/IN
functionally/RB
altered/JJ
proteins/NNS
./.
====================
In/IN
addition/NN
,/,
the/DT
editing/VBG
can/MD
have/VB
an/DT
impact/NN
on/IN
RNA/NN
splicing/NN
,/,
indicating/VBG
the/DT
interplay/NN
of/IN
these/DT
mechanisms/NNS
[/(
29/CD
]/)
./.
====================
The/DT
biological/JJ
consequences/NNS
of/IN
RNA/NN
editing/VBG
are/VBP
broadly/RB
linked/VBN
to/TO
RNA/NN
metabolism/NN
and/CC
function/NN
,/,
including/VBG
mRNA/NN
stability/NN
,/,
splicing/NN
,/,
nuclear/JJ
export/NN
,/,
and/CC
localization/NN
[/(
30/CD
]/)
./.
====================
As/IN
mentioned/VBN
,/,
A-to-I/JJ
editing/VBG
is/VBZ
detectable/JJ
from/IN
RNA-Seq/NN
data/NNS
by/IN
modifying/VBG
the/DT
analysis/NN
pipeline/NN
./.
====================
A/DT
prediction/NN
should/MD
be/VB
carefully/RB
made/VBD
due/JJ
to/TO
frequent/JJ
false/NN
positives/VBZ
arising/VBG
from/IN
single-nucleotide/JJ
polymorphisms/NNS
or/CC
sequencing/NN
errors/NNS
./.
====================
This/DT
limitation/NN
has/VBZ
been/VBN
overcome/VBN
in/IN
recent/JJ
years/NNS
by/IN
developing/VBG
bioinformatics/NNS
methods/NNS
for/IN
accurate/JJ
predictions/NNS
./.
====================
By/IN
comparing/VBG
genomic/JJ
DNA/NN
and/CC
RNA/NN
sequencing/NN
data/NNS
from/IN
the/DT
same/JJ
individuals/NNS
,/,
the/DT
biological/JJ
noise/RB
from/IN
genomic/JJ
polymorphisms/NNS
could/MD
be/VB
reduced/VBN
./.
====================
Technical/JJ
noise/RB
caused/VBD
by/IN
sequencing/NN
errors/NNS
and/CC
incorrect/VB
alignment/NN
can/MD
be/VB
removed/VBN
by/IN
focusing/VBG
on/IN
high-quality/JJ
reads/VBZ
./.
====================
Public/JJ
databases/NNS
collecting/JJ
well-annotated/JJ
edited/JJ
sites/NNS
are/VBP
also/RB
useful/JJ
for/IN
reliable/JJ
screening/NN
and/CC
functional/JJ
annotation/NN
[/(
31,32/CD
]/)
./.
====================
In/IN
the/DT
near/JJ
future/JJ
,/,
new/JJ
platforms/NNS
such/JJ
as/IN
nanopore/RB
sequencing/NN
will/MD
solve/VB
current/JJ
technical/JJ
hurdles/NNS
by/IN
allowing/VBG
direct/JJ
detection/NN
of/IN
editing/VBG
in/IN
full-length/JJ
RNA/NN
molecules/NNS
[/(
33/CD
]/)
./.
====================
Recent/JJ
advances/NNS
in/IN
RNA/NN
editing/VBG
research/NN
have/VBP
contributed/VBN
to/TO
scientists/NNS
’/CD
understanding/VBG
of/IN
the/DT
mechanisms/NNS
involved/VBN
in/IN
human/JJ
cancers/NNS
through/IN
the/DT
accumulation/NN
of/IN
evidence/NN
of/IN
mutated/VBN
peptides/NNS
induced/VBD
by/IN
RNA/NN
editing/VBG
[/(
34,35/CD
]/)
./.
====================
Through/IN
an/DT
integrated/JJ
analysis/NN
of/IN
TCGA/NN
genomic/JJ
data/NNS
and/CC
CPTAC/NN
proteomic/JJ
data/NNS
,/,
Peng/NN
et/FW
al/JJ
./.
====================
showed/VBD
that/IN
A-to-I/JJ
RNA/NN
editing/VBG
made/VBD
a/DT
notable/JJ
contribution/NN
to/TO
increased/VBN
protein/NN
diversity/NN
in/IN
human/JJ
cancers/NNS
[/(
36/CD
]/)
./.
====================
According/VBG
to/TO
their/PRP$
analysis/NN
,/,
a/DT
considerable/JJ
number/NN
of/IN
editing/VBG
events/NNS
lead/VBP
to/TO
changes/NNS
in/IN
the/DT
amino/NN
acid/NN
sequence/NN
,/,
indicating/VBG
the/DT
possibility/NN
that/IN
A-to-I/JJ
editing/VBG
may/MD
be/VB
a/DT
source/NN
of/IN
producing/VBG
mutated/VBN
peptides/NNS
./.
====================
More/RBR
direct/JJ
evidence/NN
of/IN
RNA/NN
editing/VBG
for/IN
neoantigen/NN
production/NN
was/VBD
reported/VBN
in/IN
recent/JJ
research/NN
by/IN
Zhang/NNP
et/FW
al/JJ
./.
====================
[/(
6/CD
]/)
./.
====================
Using/VBG
proteogenomics/NNS
screening/NN
,/,
they/PRP
identified/VBD
five/CD
edited/JJ
peptides/NNS
and/CC
confirmed/VBD
their/PRP$
tumor/NN
association/NN
and/CC
their/PRP$
immunogenicity/NN
regarding/VBG
T/NN
cell/NN
recognition/NN
and/CC
killing/NN
./.
====================
In/IN
addition/NN
,/,
they/PRP
showed/VBD
experimental/JJ
evidence/NN
responsible/JJ
for/IN
the/DT
biological/JJ
mechanism/NN
of/IN
RNA/NN
editing/VBG
depending/VBG
on/IN
ADAR/NN
expression/NN
./.
====================
In/IN
addition/NN
to/TO
cancer/NN
research/NN
,/,
Roth/NNP
et/FW
al/JJ
./.
====================
[/(
37/CD
]/)
provided/VBD
evidence/NN
that/IN
RNA/NN
editing/VBG
is/VBZ
significantly/RB
increased/VBD
in/IN
systemic/JJ
lupus/NN
erythematosus/NN
patients/NNS
,/,
promoting/VBG
autoimmune/JJ
progression/NN
by/IN
increasing/VBG
the/DT
autoantigenic/JJ
load/NN
./.
====================
Improvement/JJ
of/IN
neoantigen/NN
prediction/NN
from/IN
patient/NN
samples/NNS
is/VBZ
an/DT
important/JJ
issue/NN
for/IN
developing/VBG
effective/JJ
immunotherapy/NN
./.
====================
Current/JJ
approaches/NNS
to/TO
neoantigen/NN
prediction/NN
have/VBP
focused/VBN
on/IN
somatic/JJ
mutations/NNS
,/,
even/RB
though/IN
genetic/JJ
changes/NNS
affecting/VBG
protein/NN
production/NN
can/MD
occur/VB
at/IN
many/JJ
different/JJ
levels/NNS
./.
====================
Most/JJS
computational/JJ
tools/NNS
developed/VBD
so/RB
far/RB
have/VBP
aimed/VBN
to/TO
evaluate/VB
the/DT
effect/NN
of/IN
non-synonymous/JJ
DNA/NN
variants/NNS
on/IN
producing/VBG
mutated/VBN
peptides/NNS
./.
====================
Representative/JJ
analysis/NN
pipelines/NNS
such/JJ
as/IN
pVAC-Seq/JJ
[/(
38/CD
]/)
and/CC
Neopepsee/JJ
[/(
39/CD
]/)
have/VBP
been/VBN
established/VBN
for/IN
somatic/JJ
mutation/NN
analysis/NN
./.
====================
The/DT
recent/JJ
studies/NNS
described/VBN
herein/RB
suggest/VBP
that/IN
alternative/JJ
splicing/NN
and/CC
RNA/NN
editing/VBG
can/MD
serve/VB
as/IN
important/JJ
sources/NNS
of/IN
neoantigens/NNS
./.
====================
The/DT
challenge/NN
in/IN
utilizing/VBG
RNA-derived/JJ
neoantigens/NNS
is/VBZ
the/DT
development/NN
of/IN
bioinformatics/NNS
methods/NNS
with/IN
increased/VBN
accuracy/NN
and/CC
performance/NN
./.
====================
RNA-Seq/NN
is/VBZ
now/RB
a/DT
popular/JJ
technique/NN
,/,
and/CC
data/NNS
on/IN
RNA-Seq/NN
have/VBP
been/VBN
accumulating/VBG
on/IN
a/DT
daily/RB
basis/NN
./.
====================
However/RB
,/,
many/JJ
researchers/NNS
feel/NN
that/DT
it/PRP
is/VBZ
not/RB
easy/RB
to/TO
detect/VB
posttranscriptional/JJ
modifications/NNS
,/,
such/JJ
as/IN
alternative/JJ
splicing/NN
and/CC
RNA/NN
editing/VBG
./.
====================
Therefore/RB
,/,
improvement/NN
of/IN
the/DT
analysis/NN
pipeline/NN
will/MD
be/VB
required/VBN
to/TO
make/VB
the/DT
RNA-derived/JJ
neoantigen/NN
prediction/NN
more/RBR
reliable/JJ
./.
====================
Schematic/JJ
presentation/NN
of/IN
various/JJ
sources/NNS
of/IN
neoantigens/NNS
./.
====================
Somatic/JJ
mutations/NNS
in/IN
DNA/NN
(/(
red/JJ
star/NN
)/)
,/,
alternative/JJ
splicing/NN
(/(
yellow/RB
bar/JJ
)/)
,/,
and/CC
RNA/NN
editing/VBG
(/(
pink/VBP
bar/JJ
)/)
can/MD
introduce/VB
significant/JJ
modifications/NNS
of/IN
DNA/NN
or/CC
RNA/NN
molecules/NNS
./.
====================
Various/JJ
regulation/NN
steps/NNS
can/MD
induce/VB
sequence/NN
changes/NNS
in/IN
the/DT
final/JJ
gene/NN
products/NNS
,/,
and/CC
the/DT
resulting/VBG
mutated/VBN
peptides/NNS
can/MD
be/VB
presented/VBN
on/IN
MHC/NN
./.
====================
Alternative/JJ
splicing/NN
occurs/VBZ
in/IN
the/DT
cell/NN
nucleus/NN
,/,
but/CC
RNA/NN
editing/VBG
can/MD
be/VB
performed/VBN
in/IN
the/DT
nucleus/NN
and/CC
cytosol/NN
,/,
as/IN
well/RB
as/IN
within/IN
mitochondria/NN
./.
====================
The/DT
colored/JJ
circles/NNS
shown/VBN
in/IN
the/DT
cytosol/NN
indicate/VBP
amino/NN
acids/NNS
changed/VBD
by/IN
genetic/JJ
events/NNS
./.
====================
Examples/NNS
of/IN
RNA/NN
processing/NN
steps/NNS
to/TO
produce/VB
two/CD
RNA/NN
isoforms/NNS
./.
====================
Two/CD
different/JJ
mRNAs/NNS
are/VBP
produced/VBN
from/IN
alternative/JJ
splicing/NN
(/(
A/NN
)/)
and/CC
RNA/NN
editing/VBG
(/(
B/NN
)/)
./.
====================
The/DT
top/NN
panel/NN
shows/VBZ
precursor/NN
mRNAs/NNS
and/CC
the/DT
bottom/CC
shows/VBZ
mature/JJ
RNAs/NNS
after/IN
posttranscriptional/JJ
processing/NN
./.
====================
Exons/NNS
are/VBP
illustrated/VBN
as/IN
boxes/NNS
,/,
while/IN
lines/NNS
represent/VBP
introns/NNS
./.
====================
For/IN
alternative/JJ
splicing/NN
(/(
A/NN
)/)
,/,
exon/NN
skipping/NN
is/VBZ
shown/VBN
as/IN
one/CD
example/NN
of/IN
the/DT
numerous/JJ
modes/NNS
./.
====================
In/IN
this/DT
case/NN
,/,
an/DT
exon/NN
is/VBZ
selectively/RB
included/VBD
from/IN
the/DT
primary/JJ
transcript/NN
./.
====================
Constitutively/RB
expressed/VBN
exons/NNS
are/VBP
depicted/VBN
in/IN
green/CD
,/,
and/CC
alternatively/RB
spliced/VBN
exons/NNS
are/VBP
depicted/VBN
in/IN
light/JJ
blue/JJ
./.
====================
For/IN
RNA/NN
editing/VBG
(/(
B/NN
)/)
,/,
the/DT
conversion/NN
of/IN
adenosine/NN
(/(
A/DT
)/)
to/TO
inosine/VB
(/(
I/NN
)/)
is/VBZ
shown/VBN
in/IN
the/DT
double-stranded/JJ
RNA/NN
structure/NN
./.
====================
The/DT
editing/JJ
is/VBZ
catalyzed/VBN
by/IN
the/DT
adenosine/NN
deaminase/NN
acting/VBG
on/IN
RNA/NN
(/(
ADAR/NN
)/)
enzyme/NN
./.
====================
Most/JJS
events/NNS
occur/VBP
in/IN
the/DT
noncoding/JJ
region/NN
of/IN
the/DT
transcript/NN
,/,
but/CC
the/DT
minor/JJ
case/NN
showing/VBG
editing/VBG
in/IN
a/DT
coding/VBG
sequence/NN
is/VBZ
shown/VBN
in/IN
this/DT
figure/NN
./.
====================
